Prospective REALITI-A StudyTake-home Points

Prospective REALITI-A StudyTake-home Points

Background: Mepolizumab, a monoclonal antibody targeting IL-5, is of proven clinical benefit in severe asthma; however, prospective, long-term, real-world data in severe asthma are required. Research Question: What is the real-world benefit of 2 years of mepolizumab treatment in severe asthma? Study...

Full description

Saved in:
Bibliographic Details
Main Authors: Cristiano Caruso, MD, PhD, G. Walter Canonica, MD, Manish Patel, MBChB, PhD, Andrew Smith, MBChB, PhD, Mark C. Liu, MD, Rafael Alfonso-Cristancho, MD, PhD, Robert G. Price, MSc, Rupert W. Jakes, PhD, Lydia Demetriou, MSc, Antonio Valero, MD, Thomas C. Köhler, MD, Charles Pilette, MD, PhD, Geoffrey Chupp, MD, Guy Brusselle, MD, Peter Howarth, DM
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:CHEST Pulmonary
Subjects:
asthma exacerbations
long-term
mepolizumab
oral corticosteroids
real world
severe asthma
Online Access:http://www.sciencedirect.com/science/article/pii/S2949789224000734
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items